CN Patent

CN1874761A — 齐拉西酮的持续释放剂型

Assigned to Pfizer Products Inc · Expires 2006-12-06 · 19y expired

What this patent protects

提供了用于治疗精神障碍、例如精神分裂症的持续释放固体口服剂型，该口服剂型包括有效治疗所述的精神障碍的用量的齐拉西酮和药物上可接受的载体。

USPTO Abstract

提供了用于治疗精神障碍、例如精神分裂症的持续释放固体口服剂型，该口服剂型包括有效治疗所述的精神障碍的用量的齐拉西酮和药物上可接受的载体。

Drugs covered by this patent

Patent Metadata

Patent number
CN1874761A
Jurisdiction
CN
Classification
—
Expires
2006-12-06
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Products Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.